BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Deals

  Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines

  Clinigen Group plc, the global pharmaceutical and services company, has today acquired International Medical Management Corporation (‘IMMCC’), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.

  October 23, 2017

   · 

  3 min read
• Drug Development

  Transgene Release: TG1050 is Well Tolerated and Induces a Strong Specific Immune Response in Patients with Chronic Hepatitis B

  Transgene announces that the analyses conducted on patients with chronic hepatitis B receiving standard antiviral therapies and a single dose of TG1050 in the Phase I/Ib trial, confirm the good tolerability profile and demonstrate the immunogenicity of this novel therapeutic vaccine.

  October 23, 2017

   · 

  6 min read
• Drug Development

  Angle PLC: Researchers Develop Parsortix-Based Process to Efficiently Harvest Cancer Cells From Bone Marrow

  ANGLE plc., a world-leading liquid biopsy company, today announces that the Center for Women’s Health Tuebingen, Germany, has presented the first report on a successful establishment of a protocol for detecting disseminated tumour cells (DTCs) using cancer patient bone marrow with the Parsortix system.

  October 23, 2017

   · 

  6 min read